Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomised Phase II Study of PEP02, Irinotecan or Docetaxel as Second-Line Therapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
2006-006452-35Phase 2Completed
- Sponsor
- PharmaEngine Inc.
- Start
- Apr 2007
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing PEP02 (liposomal irinotecan) monotherapy, Irinotecan monotherapy and Docetaxel monotherapy (3 arms). Primary endpoint: Objective tumour response rate. Started Apr 2007; status: completed.
02
Drugs
irinotecan liposomeirinotecandocetaxel
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2006-006452-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006452-35.